Hogan Lovells Events | 4 October 2023 | 2:00 p.m. - 5:30 p.m. (JST)

Tokyo: Life Sciences and Health Care Horizons 2023

Key Life Sciences issues for Japanese companies

You are warmly invited to join us on Wednesday, 4 October in Tokyo for the next session in our global Life Sciences and Health Care Horizons series. We are delighted to be resuming an in-person seminar format for the first time since 2019. Participants will have the opportunity to hear from members of our global life sciences and health care team as they discuss key issues and regional and international developments relevant to Japanese companies, and to interact live with our international team.

Presenters will be joining from our U.S., Europe, and Japan offices, representing our FDA/EU Regulatory, Commercial, Digital Health, and Intellectual Property practices. Based on their recent experience and multi-jurisdictional projects, they will share insights from a practical and strategic perspective to help Japanese companies understand key emerging risks, challenges, and new opportunities as the global life sciences and broader legal and regulatory landscape continues to evolve.

Our planned topics include the following:

• Current life sciences regulatory trends in the U.S. and EU markets: we plan to discuss recent trends including pricing and reimbursement, early access, orphan market exclusivity and pediatric rewards, European Regulatory Data Protection reform, advancements in the European Health Technology Assessment, as well as how the U.S. Inflation Reduction Act (IRA) could impact Japanese companies operating in the U.S.
• Global trends in AI and digital health: we will analyze the latest developments in AI and digital health from a technological and compliance perspective and discuss how these changes are likely to affect Japanese companies in the future.
• Cross-border licensing transactions in life sciences: we plan to share insights from recent multi-jurisdictional licensing matters to provide strategic advice for Japanese companies involved in cross-border licensing transactions in the U.S., Europe, and Japan.